Replies to post #31947 on Biotech Values

[DewDiligence]

VRTX has honed their IR skills so they present just the right mix of hype and caution. I’m being serious, not sarcastic—I think it’s a well-managed company. The wink, wink guidance on the VX-950 timeline is a case in point.

[mskatiescarletohara]

VRTX-Lovefeast at AASLD. It appears VRTX will be making a statement via PR in a poster. Note the data is not being presented in a Plenary or Parallel session.

CONTROL ID: 258193
SESSION TITLE: HCV Therapy: Pre-clinical and Early Clinical Development
SESSION START TIME: October 30, 2006, 8:00 AM
SESSION END TIME: October 30, 2006, 5:30 PM
SESSION LOCATION: Exhibit Hall C
SESSION ROLE & SESSION HOST (ALL):
SESSION ABSTRACT START TIME: October 30, 2006, 8:00 AM
SESSION ABSTRACT END TIME: October 30, 2006, 8:00 AM

Abstract:
TITLE: Current status of subjects receiving Peg-Interferon-Alfa-2a (Peg-IFN) and Ribavirin (RBV) Follow-on therapy after 28-Day treatment with the hepatitis C protease inhibitor TELAPREVIR (VX-950), Peg-IFN AND RBV
AUTHORS/INSTITUTIONS: M. Rodriguez-Torres, , Fundación de Investigación de Diego, Santurce, PR, PUERTO RICO;
M. Rodriguez-Torres, , Ponce School of Medicine, Ponce, PR, PUERTO RICO;
E. Lawitz, , Alamo Medical Research, San Antonio, TX;
A. Muir, J.G. McHutchison, , Duke Clinical Research Institute & Division of Gastroenterology, Durham, NC;
J. Keane, T. Kieffer, L. McNair, , Vertex Pharmaceuticals Incorporated, Cambridge, MA;